Synthesis and In Silico Evaluation of the Ninhydrin Derivatives Interaction with Target Proteins Involved in Cancer Pathogenesis and Progression

References (58)

1. 1 Vavaiya, 2025, The reaction of Ninhydrin Revisited: Applications in quantification of analytes, active pharmaceutical ingredients and amino acids [DOI]
2. 2 Das, 2020, Recent applications of ninhydrin in multicomponent reactions [DOI]
3. 3 Das, A., and Banik, B.K. (2021). Chapter 6—Microwave-assisted oxidation and reduction reactions. Advances in Green and Sustainable Chemistry, Elsevier. Microwaves in Chemistry Applications. [DOI]
4. 4 Lennard, C. (2013). Forensic sciences: Fingerprint techniques. Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier.
5. 5 Pierzynowski, 2025, Algorithm and ninhydrin method allow for measurement of the postprandial appearance of peptides in blood [DOI]
6. 6 Liu, 2025, Research progress of fluorescent particle suspension technique for the visualization of latent handprints
7. 7 Menon, 2025, Three novel Schiff bases based on ninhydrin: Synthesis, characterization, DFT, anticancer, antibacterial and molecular docking studies [DOI]
8. 8 Qureshi, 2000, Studies on the cytotoxic, biochemical and anti-carcinogenic potentials of ninhydrin on Ehrlich ascites carcinoma cell-bearing Swiss albino mice [DOI]
9. 9 De, 2020, Development of highly potent Arene-Ru(II)-ninhydrin complexes for inhibition of cancer cell growth [DOI]
10. 10 Tahermansouri, 2014, One-pot Functionalization of Short Carboxyl Multi-walled Carbon Nanotubes with Ninhydrin and Thiourea via Microwave and Thermal Methods and Their Effect on MKN-45 and MCF7 Cancer Cells [DOI]
11. 11 Hansen, 2005, The development of novel ninhydrin analogues [DOI]
12. 12 Lipinski, 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [DOI]
13. 13 Park, 2001, Metabolism of fluorine-containing drugs [DOI]
14. 14 Faeh, 2007, Fluorine in pharmaceuticals: Looking beyond intuition [DOI]
15. 15 Hagmann, 2008, The many roles for fluorine in medicinal chemistry [DOI]
16. 16 Kalgutkar, 2005, Minimising the potential for metabolic activation in drug discovery [DOI]
17. 17 Marminon, 2015, Microwave-assisted oxidation of indan-1-ones into ninhydrins [DOI]
18. 18 Guedat, P., Boissy, G., Borg-Capra, C., Colland, F., Daviet, L., Formstecher, E., Jack, X., Rain, J.-C., Delansorne, R., and Peretto, I. (2026, June 08). Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications. Current Patent Assignee: HYBRIGENICS EP1798232, 20 June 2007, Location in patent: Page/Page Column 19. Available online: https://worldwide.espacenet.com/patent/search/family/036282596/publication/EP1798232A1?q=pn%3DEP1798232.
19. 19 Kornblum, 1957, A new and selective method of oxidation [DOI]
20. 20 Kornblum, 1959, A new and selective method of oxidation. The conversion of alkyl halides and alkyl tosylates to aldehydes [DOI]
21. 21 Thompson, 1991, Ninhydrin and ninhydrin analogs. Syntheses and applications [DOI]
22. 22 Heffner, 1991, Synthetic routes to ninhydrins. Preparation of ninhydrin, 5-methoxyninhydrin, and 5-(methylthio)ninhydrin [DOI]
23. 23 Tatsugi, 1998, A convenient one-pot synthesis of indane-1,2,3-triones by oxidation of indan-1-ones with N-bromosuccinimide-dimethyl sulfoxide reagent
24. 24 Chen, M., Sharma, A., Lin, Y., Wu, Y., He, Q., Gu, Y., Xu, Z.P., Monteiro, M., and Gu, W. (2019). Insulin and epithelial growth factor (EGF) promote programmed death ligand 1 (PD-L1) production and transport in colon cancer stem cells. BMC Cancer, 19. [DOI]
25. 25 Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S.C., Stefani, C., and Greabu, M. (2021). PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int. J. Mol. Sci., 22. [DOI]
26. 26 Xia, 2015, PI3K/Akt/mTOR signaling pathway in cancer stem cells: From basic research to clinical application
27. 27 Rivera, 2002, BDNF-induced TrkB activation down-regulates the K+-Cl− cotransporter KCC2 and impairs neuronal Cl− extrusion [DOI]
28. 28 Kue, 2016, Targeted delivery of a peptidomimetic ligand-photosensitizer kinase C tropomyosin receptor conjugate induces an antitumor immune response after photodynamic therapy [DOI]
29. 29 Jin, W. (2020). Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition. Cells, 9. [DOI]
30. 30 Kuramoto, K., Yamamoto, M., Suzuki, S., Togashi, K., Sanomachi, T., Kitanaka, C., and Okada, M. (2021). Inhibition of the lipid droplet-peroxisome proliferator-activated receptor α axis suppresses cancer stem cell properties. Genes, 12. [DOI]
31. 31 Tyagi, 2011, The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases [DOI]
32. 32 Laudadio, 2023, Mechanistic insight toward EGFR activation induced by ATP: Role of mutations and water in ATP binding patterns [DOI]
33. 33 Venkateswaran, 2023, Identification of potential phytochemical inhibitors from Conium maculatum targeting the epidermal growth factor receptor in metastatic colorectal cancer via molecular docking analysis
34. 34 Maldonado, J., Oliva, A., Guzmán, L., Molinari, A., and Acevedo, W. (2024). Synthesis, anticancer activity, and docking studies of novel hydroquinone-chalcone-pyrazoline hybrid derivatives. Int. J. Mol. Sci., 25. [DOI]
35. 35 Ibrahim, 2023, Theoretical validation of some third-generation epidermal growth factor receptor (EGFR) inhibitors as non-small cell lung cancer (NSCLC) drugs
36. 36 Ahsan, 2015, Synthesis, anticancer activity and molecular docking studies of newer quinoline analogues
37. 37 Radwan, A.A., Alanazi, F., and Al-Dhfyan, A. (2024). Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation. PLoS ONE, 19. [DOI]
38. 38 Abdullahi, 2022, In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line [DOI]
39. 39 Ibrahim, 2021, Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: A computational approach [DOI]
40. 40 Abdellattif, 2024, Novel candidates synthesis of indenopyrazole, indenoazine and indenothiophene, with anticancer and in silico studies [DOI]
41. 41 Dera, A.A., Zaib, S., Hussain, N., Rana, N., Javed, H., and Khan, I. (2023). Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer. Molecules, 28. [DOI]
42. 42 Wadi, 2022, Mulberroside A could serve as a pan inhibitor for the tyrosine kinase domains of the HER family [DOI]
43. 43 Sonar, 2022, Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors [DOI]
44. 44 Sahu, 2017, Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy [DOI]
45. 45 Zaraei, 2021, Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors [DOI]
46. 46 Haybaeck, 2009, A lymphotoxin-driven pathway to hepatocellular carcinoma [DOI]
47. 47 Hu, 2015, Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin β receptors [DOI]
48. 48 Dejardin, 2002, The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways [DOI]
49. 49 Boehm, 2003, Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTβR [DOI]
50. 50 Li, Y., Li, F., Qin, D., Chen, H., Wang, J., Wang, J., Song, S., Wang, C., Wang, Y., and Liu, S. (2022). The role of brain derived neurotrophic factor in central nervous system. Front. Aging Neurosci., 14. [DOI]
51. 51 Leopold, 2019, Neurotrophin receptor tyrosine kinases regulated with near-infrared light [DOI]
52. 52 Junior, 2020, Role of tropomyosin-related kinase B receptor and brain-derived neurotrophic factor in cancer [DOI]
53. 53 Ateaque, S., Merkouris, S., and Barde, Y.A. (2023). Neurotrophin signalling in the human nervous system. Front. Mol. Neurosci., 16. [DOI]
54. 54 Chaldakov, G.N., Aloe, L., Yanev, S.G., Fiore, M., Tonchev, A.B., Vinciguerra, M., Evtimov, N.T., Ghenev, P., and Dikranian, K. (2024). Trackins (Trk-targeting drugs): A novel therapy for different diseases. Pharmaceuticals, 17. [DOI]
55. 55 Haniu, 1997, Interactions between brain-derived neurotrophic factor and the TrkB receptor [DOI]
56. 56 Kaupang, 2015, Involvement of covalent interactions in the mode of action of PPARβ/δ antagonists [DOI]
57. 57 Wang, 2019, Antcins, triterpenoids from Antrodia cinnamomea, as new agonists for peroxisome proliferator-activated receptor α [DOI]
58. 58 Capelli, 2016, Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode [DOI]

Cited by 0

No indexed citations yet.

Related research

• Does Pain Adversely Affect the Quality of Life in Hospitalized Cancer Patients? — shares topic coverage
• Complementary Medicine Intervention in Breast Cancer Patients with Pain — shares topic coverage
• Use of Performance Status Score for Cytotoxic Chemotherapy among Surgeons in a Tertiary Hospital, Southern Nigeria — shares topic coverage
• Breast Self Examination and Cancer Awareness among Female Staff in Federal Medical Center, Yenagoa, Bayelsa State (Knowledge and Practice) — shares topic coverage
• Assessment of Cancer Risk from Fluorscopic Bile Duct Examinations at Sanjiwani Hospital, Gianyar — shares topic coverage